Open AccessMortality from COVID-19 in patients with tuberculosis: systematic review and meta-analysis
Author(s) -
I. B. Lebedeva,
М. А. Шмакова,
О. М. Дроздова,
Е. Б. Брусина
Publication year - 2022
Publication title -
fundamentalʹnaâ i kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2542-0941
pISSN - 2500-0764
DOI - 10.23946/2500-0764-2022-7-1-78-85
Subject(s) - medicine , tuberculosis , cochrane library , meta analysis , odds ratio , confidence interval , covid-19 , cohort study , adverse effect , medline , disease , pathology , infectious disease (medical specialty) , political science , law
Aim. To perform a systematic analysis of COVID-19 adverse outcomes in patients with tuberculosis. Materials and Methods. We queried PubMed, Cochrane Library, Embase, ClinicalTrials.gov, medRxiv, bioRxiv, and Elibrary databases for studies on COVID-19-related mortality in patients with tuberculosis published from 2020 to 2022. We considered open randomised controlled trials, cohort, and case-control studies. Pseudorandomisation and interventional studies have been excluded from the analysis as well as those without a clear comparison group (i.e., patients without tuberculosis) and duplicate studies. Results. Out of 23,296 hits, 10 studies were included in our review. The risk of death in patients with COVID-19 and tuberculosis was significantly higher (odds ratio = 2.24, 95% confidence interval = 1.46 – 3.43] as compared with the patients without tuberculosis. Conclusion. Tuberculosis is associated with COVID-19-related mortality.